glp 1 france to become the first country in Europe to reimburse weight-loss drugs France Expands Access to GLP-1

A randomised controlled trial was conducted in 2022 investigating the impact of semaglutide and liraglutide on weight loss in individuals living with obesity

Semaglutides starting dose begins at a modest .25mg, usually administered as a weekly injection, and gradually escalates to a target dose of 2.4mg after roughly 16 weeks

STUDY DESIGN, SIZE, DURATION This nationwide observational cohort study used data from Danish health registries from October 2009 through December 2023

Pharmacokinetic Profiles of Available Agents The pharmacokinetic diversity amongst GLP-1 RAs has important implications for perioperative decision-making (Table 1)